DGAT2L6 Inhibitors
DGAT2L6 Inhibitors consist of a variety of compounds that interfere with the enzymatic activity of DGAT2L6, which is primarily involved in the synthesis of triglycerides by esterifying fatty acids. Inhibitors such as a lipase inhibitor directly impair DGAT2L6 by preventing the formation of the ester bond in triglycerides, crucial for the storage of fats within cells. Other compounds achieve this inhibition by reducing the availability of substrates necessary for the enzyme's activity; these include inhibitors of fatty acid synthase, which disrupt de novo synthesis of fatty acids, and inhibitors of enzymes like stearoyl-CoA desaturase and acetyl-CoA carboxylase, which are essential for the production of fatty acid substrates. The outcome of such inhibition is a decreased synthesis of triglycerides, as the reduced pool of fatty acids available for esterification limits DGAT2L6's functional role in lipid storage.
Furthermore, some inhibitors act on proteins that modulate the intracellular levels of diacylglycerol and other intermediates in the lipid synthesis pathway, which serve as substrates for DGAT2L6. For instance, DGAT1 inhibitors can indirectly influence DGAT2L6 activity by altering the balance of these intermediates. Additionally, compounds that inhibit the uptake of fatty acids into cells, by targeting fatty acid translocases, can lead to a reducedsubstrate availability for DGAT2L6, thus impacting its activity in triglyceride synthesis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lipase Inhibitor, THL | 96829-58-2 | sc-203108 | 50 mg | $52.00 | 7 | |
This lipase inhibitor directly impairs the enzymatic activity of DGAT2L6 by inhibiting the esterification of fatty acids on the triglyceride molecule, thus preventing the storage of fats. | ||||||
Cerulenin (synthetic) | 17397-89-6 | sc-200827 sc-200827A sc-200827B | 5 mg 10 mg 50 mg | $161.00 $312.00 $1210.00 | 9 | |
This fatty acid synthase inhibitor disrupts the de novo synthesis of fatty acids, hence decreasing the substrate availability for DGAT2L6 catalyzed triglyceride synthesis. | ||||||
C75 (racemic) | 191282-48-1 | sc-202511 sc-202511A sc-202511B | 1 mg 5 mg 10 mg | $72.00 $206.00 $290.00 | 9 | |
By inhibiting fatty acid synthase, this compound limits the production of fatty acids, thus reducing the availability of these substrates for DGAT2L6, thereby decreasing triglyceride synthesis. | ||||||
Atglistatin | 1469924-27-3 | sc-503147 | 5 mg | $330.00 | ||
A selective adipose triglyceride lipase inhibitor that prevents the breakdown of triglycerides into fatty acids, leading to a reduced substrate flow through lipid metabolism pathways where DGAT2L6 is involved. | ||||||
A 922500 | 959122-11-3 | sc-203793 | 10 mg | $270.00 | 2 | |
This selective DGAT1 inhibitor may exert indirect inhibition on DGAT2L6 by modulating the intracellular levels of diacylglycerol, a substrate for both DGAT enzymes. | ||||||
Sulfosuccinimidyl oleate sodium | 135661-44-8 | sc-208408B sc-208408 sc-208408A sc-208408C | 10 mg 25 mg 50 mg 250 mg | $245.00 $418.00 $734.00 $2913.00 | 17 | |
This inhibitor of CD36, a fatty acid translocase, reduces fatty acid uptake into cells, thereby lowering the availability of fatty acids for DGAT2L6-mediated triglyceride synthesis. | ||||||
Xanthohumol from hop (Humulus lupulus) | 6754-58-1 | sc-301982 | 5 mg | $361.00 | 1 | |
This prenylflavonoid inhibits the activity of enzymes involved in fatty acid synthesis, such as fatty acid synthase, thereby reducing the availability of fatty acids for DGAT2L6 to use in triglyceride synthesis. | ||||||
Betulinic Acid | 472-15-1 | sc-200132 sc-200132A | 25 mg 100 mg | $117.00 $344.00 | 3 | |
By inhibiting stearoyl-CoA desaturase, it reduces the levels of unsaturated fatty acids, which are substrates for DGAT2L6, thus affecting the triglyceride synthesis pathway. | ||||||